Skip to main content

CARACTERIZACION DE DETERMINANTES GENETICOS RELEVANTES PARA EL DESARROLLO DE UNA VACUNA FRENTE AL VIRUS DE LA PESTE PORCINA AFRICANA

RTI2018-097305-R-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2018
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO NACIONAL DE INVESTIGACIÓN Y TECNOLOGÍA AGRARIA Y ALIMENTARIA - CSIC

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Identification of NPC1 as a novel SARS-CoV-2 intracellular target

  • García-Dorival, Isabel
  • Cuesta-Geijo, Miguel Ángel
  • Barrado-Gil, Lucía
  • Galindo, Inmaculada
  • Urquiza, Jesús
  • Puerto, Ana del
  • Gil, Carmen
  • Campillo, Nuria E.
  • Martínez Gil, Ana
  • Alonso, Covadonga
Niemann-Pick type C1 (NPC1) receptor is an endosomal membrane protein that regulates intracellular cholesterol trafficking, which is crucial in the Ebola virus (EBOV) cycle. The severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) enters the cell by binding of the viral spike (S) protein to the ACE2 receptor. This requires S-protein processing either by the surface transmembrane serine protease TMPRSS2 for plasma membrane fusion or cathepsin L for endosomal entry. Additional host factors are required for viral fusion at endosomes. Here, we report a novel interaction of the SARS-CoV-2 nucleoprotein (N) with the cholesterol transporter NPC1. Moreover, small molecules interfering with NPC1 that inhibit EBOV entry, also inhibited human coronavirus. Our findings suggest an important role for NPC1 in SARS-CoV-2 infection, a common strategy shared with EBOV, and a potential therapeutic target to fight against COVID-19., This research was partially supported through “La Caixa” Banking Foundation (HR18-00469), Instituto de Salud Carlos III (ISCIII-COV20/01007), CSIC (201980E024 and 202020E079), Spanish Ministry of Science and Innovation (RTI2018-097305-R-I00) and the European Commission Horizon 2020 Framework Programme VACDIVA-SFS482 12-2019-1-862874., No